EUVIMEDEUVIMED entdecken
Crossref

Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy

Sina Monfared, Sumedh Kaul, Jamil Almohtasib, Aaron Fleishman, Agustin Perez-Londoño, Ruslan Korets, Peter Chang, Andrew Wagner, Simon Kim, Joaquim Bellmunt, Nima Aghdam, Aria F Olumi und 1 weitere

Canadian Urological Association Journal · 20.08.2026 · 20 (12)

DOI: 10.5489/cuaj.9678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 20.08.2026. Verfasst von Sina Monfared und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although a single randomized trial demonstrated improved survival with adjuvant chemotherapy (AC) for locally advanced (pT2-4 or N+) upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU), this survival benefit was not observed in pT2 or N+ patients, and real-world data are lacking. We therefore emulated the completed POUT trial using a large, nationwide cancer registry.

Methods

We identified patients aged 50−79 years with pT2−4 or pN+, non-metastatic UTUC treated with RNU from 2006−2020 in the National Cancer Database (NCDB). A propensity score for receipt of multiagent AC within three months of RNU was estimated using logistic regression, and the associations of AC with overall survival (OS) were evaluated after reweighting by stabilized inverse probability of treatment weights (sIPW).

Results

The study cohort comprised 3206 patients, of whom 802 (25%) received AC. pT stage was £pT2 in 954 (30%) patients, and 167 (5%) patients had pN+ disease. Median followup was 47.0 (interquartile range 24.0−86.0) months. After IPW-reweighting, AC was not associated with improved OS compared to observation, with five-year OS of 60% vs. 58%, respectively (hazard ratio 0.92, 95% confidence interval 0.79−1.08, p=0.30). When examining treatment effects across baseline characteristics, AC was not associated with improved survival for any pT or pN category.

Conclusions

In analyses designed to emulate the POUT trial, we did not observe improved OS with AC in the overall cohort, nor in specific pT or pN categories. These findings suggest the need to examine the real-world comparative effectiveness of AC in locally advanced UTUC in further studies.

Autor:innen und Institutionen

  • Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States.
  • Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States.
  • Division of Urology, University of Colorado Anschutz Medical Center, Aurora, CO, United States.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States.

Zitieren

APA

Monfared, S., Kaul, S., Almohtasib, J., Fleishman, A., Perez-Londoño, A., Korets, R., Chang, P., Wagner, A., Kim, S., Bellmunt, J., Aghdam, N., Olumi, A. F., & Gershman, B. (2026). Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy. Canadian Urological Association Journal, 20(12). https://doi.org/10.5489/cuaj.9678

Vancouver

Monfared S, Kaul S, Almohtasib J, Fleishman A, Perez-Londoño A, Korets R, et al. Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy. Canadian Urological Association Journal. 2026;20(12). doi:10.5489/cuaj.9678

BibTeX
@article{Monfared2026,
  author = {Monfared, Sina and Kaul, Sumedh and Almohtasib, Jamil and Fleishman, Aaron and Perez-Londoño, Agustin and Korets, Ruslan and Chang, Peter and Wagner, Andrew and Kim, Simon and Bellmunt, Joaquim and Aghdam, Nima and Olumi, Aria F and Gershman, Boris},
  title = {Adjuvant chemotherapy vs. observation for locally advanced upper tract urothelial carcinoma following radical nephroureterectomy},
  journal = {Canadian Urological Association Journal},
  year = {2026},
  volume = {20},
  number = {12},
  doi = {10.5489/cuaj.9678}
}
Kostenlos starten →